Upstate Active Clinical Trials

Study Title:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

What is the purpose of the study?

• Whether Baricitinib combined with standard therapy can help patients with SLE.
• The safety of Baricitinib and any side effects you might have when you take it.

Upstate Institutional Review Board (IRB) Number:

1400189

Study/Protocol ID:

I4V-MC-JAIA

Study Phase:

N/A

Patient Age Group:

Adults

Principal Investigator:

Andras Perl, MD, PhD

Who can I contact for more information?

Name: Joanne M Chilton, CCRP
Phone: 315-464-8240
Email: chiltonj@upstate.edu

Return to Previous Page || Search Again

Top